CBRN & biodefense
Every tracked article in this category, most recent first.
1listed cbrn & biodefense stocks
by convictionSaudi Arabia’s nuclear program could outlive its government, so plan accordingly
Experts are advising U.S. lawmakers on the long-term strategic implications and risks associated with the proliferation of nuclear technology programs in Saudi Arabia.
Emergent BioSolutions stock falls as CFO plans retirement
Yahoo Finance
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Yahoo Finance
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
Yahoo Finance
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Yahoo Finance
The NIH-Pentagon deal isn’t a cash grab. It’s a rescue.
Former Pentagon official David Lasseter argues that integrating defense capabilities with scientific innovation, such as biodefense initiatives, is critical to addressing rapidly evolving global security threats.
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
Yahoo Finance
Overlooking the obvious: The most likely way AI can enable terror attacks
This article discusses the risks associated with AI-enabled terror, specifically identifying the development of engineered biological agents and nuclear weapons as primary national security concerns.
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Yahoo Finance
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
Yahoo Finance
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
Yahoo Finance
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript
Yahoo Finance
Why Did TTD, PZZA, EBS Stocks Plummet To 52 Week Lows?
Yahoo Finance
Emergent Biosolutions Q2 Earnings Call Highlights
Yahoo Finance
Emergent BioSolutions Inc. Q2 2026 Earnings Call Summary
Yahoo Finance
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
Yahoo Finance
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
Yahoo Finance
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Emergent BioSolutions was awarded a $52.7 million contract modification by the U.S. government to supply ACAM2000 vaccine and related materials for smallpox preparedness.
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions received a $64.5 million contract modification from the U.S. government to supply its Botulism Antitoxin (BAT) for national biodefense purposes.
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
Emergent BioSolutions' ACAM2000 vaccine has received approval from Singapore’s Health Sciences Authority for expanded use in preventing mpox.